PURPOSE Hepatic arterial infusion (HAI) has been proved to be an effective strategy to increase the chances of resection for colorectal cancer patients with liver metastasis (CRCLM). Herein, we aimed to evaluate the benefits and risks of initial treatment with HAI floxuridine (FUDR) and systemic XELOX in un-resectable synchronous CRCLM. MATERIALS AND METHODS HAI catheter systems were implante...

Researchers have temporarily halted accrual to a trial of bevacizumab (Avastin) and two chemotherapy regimens for early-stage colon cancer after they found an unexpected number of non-cancer-related deaths in one of the study arms. The data safety monitoring board (DSMB) recommended that enrollment be delayed until 60-day mortality data could be collected and reviewed for all patients currently...

Methods: 33 pts with progressive well differentiated NETs (G1,G2) were treated with everolimus 10 mg q.d. combined with octreotide LAR 30-40 mg till progression or intolerable toxicity. All pts were evaluable for efficacy and toxicity. The mean age was 54 years (25-72), 11 male, 22 female. The most of pts had pancreatic NETs–13 (39%) pts. There were 19 (57,6%) NETs of foregut origin, 8 (24,2%) ...

BACKGROUND Colorectal cancer is one of the most frequent and lethal cancers. The aim of this study was to analyze the costs relating to treatment of colorectal cancer between Xelox and Folfox-4 at a regional level according to the clinical experience at an Italian hospital in Lombardy. METHODS A cost analysis was carried out regarding resource consumption by patients suffering from colorectal...

PURPOSE Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (mFOL- FOX6) or capecitabine/oxaliplatin (XELOX). METHODS We designed a two-arm retrospective study of mCRC patient...

BACKGROUND In stage III colon cancer, oxaliplatin/5-fluorouracil (5-FU)-based adjuvant chemotherapy (FOLFOX) improves disease-free survival (DFS) and overall survival (OS). In rectal adenocarcinoma following neoadjuvant chemoradiation (CRT), we examined the benefit of postoperative adjuvant capecitabine and oxaliplatin (XELOX) chemotherapy. METHODS Eligible patients were randomly assigned fol...

BACKGROUND The start of chemotherapy usually requires a delay of about 4 weeks after surgical resection of colorectal cancer. However, there is no evidence for the required length of this delay interval. In addition, there is a chance that a patient may die because postoperative chemotherapy was not started soon enough and a metastatic tumor was able to develop rapidly. We therefore conducted a...

PURPOSE There is substantial germline genetic variability within angiogenesis pathway genes, thereby causing interindividual differences in angiogenic capacity and resistance to antiangiogenesis therapy. We investigated germline polymorphisms in genes involved in VEGF-dependent and -independent angiogenesis pathways to predict clinical outcome and tumor response in metastatic colorectal cancer ...

Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response. Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third l...

BACKGROUND To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy. PATIENTS AND METHODS A total of 627 patients were randomly assigned to receive XELOX (n = 313) or FOLFOX-4 (n = 314) following disease ...